BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30699313)

  • 1. CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma.
    Advani R; Volkmer JP; Chao MP
    N Engl J Med; 2019 Jan; 380(5):497-498. PubMed ID: 30699313
    [No Abstract]   [Full Text] [Related]  

  • 2. CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma.
    Li Y
    N Engl J Med; 2019 Jan; 380(5):497. PubMed ID: 30702241
    [No Abstract]   [Full Text] [Related]  

  • 3. CD47 Blockade and Rituximab in Non-Hodgkin’s Lymphoma.
    Valerius T; Rösner T; Leusen JHW
    N Engl J Med; 2019 Jan; 380(5):496-7. PubMed ID: 30702240
    [No Abstract]   [Full Text] [Related]  

  • 4. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
    Advani R; Flinn I; Popplewell L; Forero A; Bartlett NL; Ghosh N; Kline J; Roschewski M; LaCasce A; Collins GP; Tran T; Lynn J; Chen JY; Volkmer JP; Agoram B; Huang J; Majeti R; Weissman IL; Takimoto CH; Chao MP; Smith SM
    N Engl J Med; 2018 Nov; 379(18):1711-1721. PubMed ID: 30380386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
    Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
    Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
    Hainsworth JD
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hodgkin's and non-Hodgkin's lymphomas.
    Rademaker J
    Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cell non-Hodgkin's lymphoma: rituximab safety experience.
    Mohrbacher A
    Arthritis Res Ther; 2005; 7 Suppl 3(Suppl 3):S19-25. PubMed ID: 15960818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.
    Chao MP; Alizadeh AA; Tang C; Myklebust JH; Varghese B; Gill S; Jan M; Cha AC; Chan CK; Tan BT; Park CY; Zhao F; Kohrt HE; Malumbres R; Briones J; Gascoyne RD; Lossos IS; Levy R; Weissman IL; Majeti R
    Cell; 2010 Sep; 142(5):699-713. PubMed ID: 20813259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review.
    Vettori S; Staibano S; Mascolo M; Ilardi G; Valentini G
    Clin Rheumatol; 2010 Jan; 29(1):1-6. PubMed ID: 19809778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.
    Arredondo-Garza T; Majluf-Cruz A; Vela-Ojeda J; Mariscal-Ramírez I; Solis-Anaya L; Lopez-Gutiérrez JR; Guadarrama CH; Rico-Curiel E; Armenta-San Sebastián JA; Castañeda-Hernández G
    Arch Med Res; 2013 Oct; 44(7):549-54. PubMed ID: 24120421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pioneer experience in Malaysia on In-house Radio-labelling of (131)I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose (131)I-rituximab-BEAM conditioning autologous transplant.
    Kuan JW; Law CS; Wong XQ; Ko CT; Awang ZH; Chew LP; Chang KM
    Appl Radiat Isot; 2016 Oct; 116():13-21. PubMed ID: 27472826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States: Implications for Nursing Practice.
    Dawson K
    J Infus Nurs; 2015; 38 Suppl 6():S4-S10. PubMed ID: 26536411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma in a patient with systemic non-Hodgkin's lymphoma.
    Svozílková P; Heissigerová J; Brichová M; Kalvodová B; Dvořák J; Ríhová E
    Virol J; 2013 Jan; 10():18. PubMed ID: 23295015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monoclonal antibody therapy for non-Hodgkin's lymphoma].
    Paul F; Rossi JF; Cartron G
    Rev Prat; 2010 Jan; 60(1):59-63. PubMed ID: 20222313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
    King KM; Younes A
    Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and preliminary evaluation of
    Suman SK; Kameswaran M; Mallia M; Mittal S; Dash A
    Appl Radiat Isot; 2019 Nov; 153():108808. PubMed ID: 31325798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.